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ROBERT RINKENBERGER, MD,* PATRICK TCHOU, MD, MASOOD AKHTAR, MD, FACC 
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To determine the efficacy of encainide in the treatment of 
atrioventricular (AV) node reentrant tachycardia, Holter 
electrocardiographic (ECG) monitoring, exercise treadmill 
testing and programmed electrical stimulation were per- 
formed in 16 patients while they were taking no medication 
and after steady state levels were reached during treatment 
with encainide (75 to 200 mg/day; mean 117 + 47). In 
addition, to study the possible reversal of drug effects by 
sympathetic stimulation, AV node conduction and tachy- 
cardia induction were reassessed during isoproterenol infu- 
sion (1 to 3 pg/min), a dose calculated to increase the rest 
heart rate by 25 + 10%. 
Sustained AV node reentrant tachycardia could be 
initiated in all 16 patients in the control state, in 2 patients 
after encainide and in 10 patients during isoproterenol 
infusion. The shortest mean atria1 paced cycle length sus- 
taining 1:l AV conduction was 358 -C 57 ms during the 
control study, which increased to 409 f 59 ms with 
encainide (p < 0.01 versus control) and decreased to 313 r 
31 ms during isoproterenol infusion (p < 0.01 versus 
control and encainide). The shortest mean ventricular 
paced cycle length with 1:l ventriculoatrial conduction was 
337 f 56 ms in the control study, 551 t 124 ms with 
encainide infusion (p < 0.01 versus control) and 354 f 72 
ms during isoproterenol infusion in the encainide-loaded 
state (p < 0.01 versus both control and encainide). 
During a mean follow-up period of 19 + 10 months, 
significant clinical recurrences occurred in 4 of the 10 
patients in whom tachycardia could still be initiated with 
encainide (with or without isoproterenol). In contrast, no 
significant episodes occurred in the six patients in whom 
tachycardia could not be induced with encainide despite 
isoproterenol infusion. Suppression of atria1 or ventricular 
ectopic activity with encainide during Holter ECG moni- 
toring did not appear to correlate with clinical recurrence. 
It is concluded that: 1) encainide is an effective agent for 
control of AV node reentrant tachycardia, primarily by 
virtue of its depressant effect on retrograde pathways; and 
2) failure to induce tachycardia in the medicated state 
despite isoproterenol infusion predicts freedom from tachy- 
cardia recurrence. 
(J Am Co11 Cardiol1989;13:904-10) 
The clinical efficacy of encainide in paroxysmal atrioventric- 
ular (AV) node reentrant tachycardia has not been exten- 
sively studied, although a preliminary report (1) has sug- 
gested good results. Even though limited data indicate that 
this efficacy is related to a depressant effect on the AV node 
(l), the effect of the drug on AV node conduction and the 
manner in which this relates to clinical control of the 
arrhythmia have never been closely scrutinized. Moreover, 
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control of tachycardia in the electrophysiology laboratory 
may not predict clinical control, possibly because of fluctu- 
ations of autonomic tone in the ambulatory state (2,3). Both 
sympathetic and vagal stimulation are known to influence 
AV node conduction, and changes in autonomic modulation 
could potentially negate the beneficial effects of the drug. 
The intent of the present study was to 1) determine the 
efficacy of encainide in treating AV node tachycardia with 
use of programmed electrical stimulation, Holter electrocar- 
diographic (ECG) monitoring, exercise treadmill testing and 
long-term clinical follow-up; 2) examine the effect of encai- 
nide on anterograde and retrograde pathways in patients 
with AV node tachycardia; 3) assess the reversal of drug 
effect on AV conduction by isoproterenol (used to simulate 
intrinsic sympathetic stimulation); and 4) evaluate the clini- 
cal implications of such reversal. 
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Methods 
Patient characteristics and selection. The patient group 
consisted of 3 men and I3 women, having a mean age of 54 
t 17 years. who were referred to either center for evaluation 
and treatment of difficult to control paroxysmal supraven- 
tricular tachycardia. A clinical history of supraventricular 
tachycardia was present for an average duration of 1 I .3 i- 
10.4 years (range 1 to 33). The frequency of clinical episodes 
was occasional (> I but <4/years) in 3 patients, frequent (>I/ 
month) in 11 patients and daily in 2 patients. None of the 
patients had incessant tachycardia. Four patients had expe- 
rienced syncopal episodes in the past, and one had required 
direct current cardioversion. An average of 2.6 2 1.7 drugs, 
including a beta-adrenergic blocker, had been used unsuc- 
cessfully before inclusion in this study. Atherosclerotic heart 
disease and hypertension were each present in four patients, 
and mitral valve prolapse was present in three patients: five 
patients had no structural heart disease. 
Halter monitoring. Holter ECG monitoring was per- 
formed with use of an ACS Tech II recorder and Cardiac 
Data Corporation Mark IV analyzer. All Holter recordings 
were analyzed in a blinded fashion by Cardio Data Systems 
(Haddonfield). A single 24 h Holter monitor was recorded in 
each patient after a 1 week washout of prior medications. 
Once adequate arrhythmic control with encainide had been 
achieved (judged by noninducibility of the arrhythmia during 
programmed electrical stimulation and absence of spontane- 
ous recurrences), another 24 h Holter monitor was repeated. 
Exercise stress testing. Maximal exercise stress testing 
was performed in II patients while they were taking no 
medication and was repeated after adequate arrhythmia 
control had been achieved with encainide. The remaining 
five patients could not undergo stress testing because of 
arthritis or other physical limitations. After noninvasive 
evaluation (in the drug-free state) had been completed, all 
patients underwent baseline electrophysiologic testing. 
Programmed stimulation. Right heart catheterization was 
performed in the nonsedated postabsorptive state after in- 
formed consent had been obtained. Under fluoroscopic 
guidance, multipolar electrode catheters were positioned in 
the region of the high right atrium. tricuspid valve and right 
ventricular apex. When feasible, a fourth catheter was 
positioned in the coronary sinus. All intracardiac electro- 
grams (filtered at frequency settings of 30 to 500 Hz), along 
with surface ECG leads I, II and V,, were displayed on a 
multichannel oscilloscope and simultaneously recorded on 
magnetic tape and paper (speed 100 mm/s) with use of an 
inkjet recorder. Pacing stimuli were provided by a Bloom 
programmable digital stimulator at a current amplitude twice 
diastolic threshold and a pulse width of 2 ms. 
The pucing protocol used included incremental atrial and 
ventricular pacing performed up to the onset of anterograde 
or retrograde Wenckebach conduction phenomenon or up to 
a maximal heart rate of 220 beatsimin. Refractory periods 
were determined with the extrastimulus technique at basic 
drives of 400 and 600 ms cycle lengths. The electrophysio- 
logic diagnosis of AV node reentrant tachycardia was based 
on previously published criteria (4-7). When two atria1 
extrastimuli were required for induction of tachycardia. 
double stimuli were also used while the patient was taking 
encainide, as well as during isoproterenol infusion. All 
episodes of induced AV node tachycardia. including those 
initiated during isoproterenol infusion, were terminated with 
atrial or ventricular pacing. No complications occurred 
during any study. 
Atrio\~entricular node tuchyuwdia NWIS inducible Mith 
programmed stimulation in ull patients \z,hile they were 
faking no medicution. Encainide was started at an initial 
dose of 75 mgiday (administered in three divided doses). In 
patients with very frequent episodes, the dosage was incre- 
mentally increased every 72 h until spontaneous tachycardia 
episodes were completely suppressed. In the remaining 
patients, the starting dosage (75 mgiday) was adhered to 
unless tachycardia recurred after loading. Once steady state 
levels had been achieved on the lowest clinically effective 
dose of encainide, programmed stimulation was repeated in 
all patients. If sustained tachycardia was still inducible. the 
dose of encainide was increased by 30 to 4.5 mgiday and 
programmed stimulation was repeated after steady state 
levels had been achieved. If sustained tachycardia was no 
longer inducible with encainide or was inducible but slower. 
isoproterenol infusion was started at a dose of I pgimin and 
titrated to achieve a minimal 15% increase in the rest heart 
rate. A mean increase of 26 z 7% was achieved overall, with 
use of an infusion rate of 1 to 3 pg/min. Programmed 
stimulation was repeated during isoproterenol infusion. In- 
ducibility of tachycardia by programmed stimulation during 
isoproterenol infusion was not considered an indication for 
increasing the encainide dose. 
Follow-up. Fourteen patients were discharged while re- 
ceiving the dose of encainide on which sustained AV node 
tachycardia could not be induced by programmed electrical 
stimulation. The remaining two patients were discharged 
while taking encainide, even though tachycardia remained 
inducible, because the induced rhythm was extremely slow. 
The mean encainide dose at discharge was 117.5 t mgiday 
administered in three equal divided doses. 
Statistical analysis. Students paired f test and Wilcoxon 
analysis (paired samples) were employed for statistical anal- 
ysis. Statistical significance was defined as p 5 0.01. Values 
are expressed as mean values t 1 SD. 
One 24 h Holter monitor was performed on al1 patients 
while they were taking no drugs and repeated immediately 
after discharge on encainide therapy. Each patient was 
provided with a transtelephonic monitoring device that was 
to be activated if symptoms recurred. A 24 h Holter record- 
ing was obtained from each patient every 6 months. Addi- 
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tional Holter monitoring was performed if patients had two patients (Patients 9 and 14) who previously had intact 
symptoms or tachycardia recurrence detected by transtele- VA conduction. However, with the addition of isoproterenol 
phonic monitoring. Monthly outpatient visits and frequent infusion, it shortened significantly to 354 t 72 ms (p < O.Ol), 
communication by telephone formed part of the study pro- with reversal of VA block in Patients 9 and 14 (Table 1, Fig. 
tocol. 1A). 
Results 
The results of electrophysiologic evaluation with pro- 
grammed electrical stimulation in the 16 patients are sum- 
marized in Table 1 and detailed below. 
Inducibility of AV node tacbycardia. Sustained tachycar- 
dia was inducible in all 16 patients in the drug-free state. In 
15 patients, it was of the “common” variety, incorporating a 
slow anterograde and a fast retrograde pathway. The remain- 
ing patient had “uncommon” (fast-slow) AV node tachycar- 
dia. 
While receiving a stable dose of encainide, only two 
patients had sustained tachycardia inducible with pro- 
grammed stimulation. In two additional patients, non- 
sustained runs of tachycardia (4 to 14 beats in length) could 
be initiated. One to three atria1 echo beats were inducible in 
five patients, and not even a single echo beat was seen in the 
remaining seven patients, although the AV node conduction 
delays achieved exceeded those that had allowed initiation 
of AV node tachycardia during the control study. 
During isoproterenol infusion, sustained tachycardia was 
initiated in 8 of the 14 patients in whom it had not been 
previously inducible during treatment with encainide. The 
tachycardia cycle length was significantly shorter in the two 
patients in whom it had been inducible during encainide 
therapy (Table 1). 
Site of block. During encainide therapy, not even a single 
atria1 echo beat could be induced in seven patients during 
introduction of atria1 extrastimuli, despite the achievement 
of AV node conduction delays exceeding those that resulted 
in the initiation of the tachycardia on baseline study. The site 
of the block was considered to be in the retrograde limb of 
the reentrant circuit in these patients. In seven patients, 1 to 
14 AV node echo beats were elicited with programmed 
stimulation, although sustained tachycardia was not induc- 
ible. Reentry terminated as a result of conduction block in 
the retrograde pathway (no atria1 echo beat after the last V 
electrogram) in six patients and in both anterograde (no V 
electrogram after the last atria1 echo beat) and retrograde 
pathways in the remaining patient. Thus, all 14 patients who 
did not have inducible sustained AV node tachycardia on 
encainide therapy had developed block in the retrograde 
limb of the tachycardia circuit. 
Retrograde conduction. On baseline evaluation, the 
shortest ventricular paced cycle length sustaining 1: 1 retro- 
grade ventriculoatrial (VA) conduction was 337 ? 56 ms. On 
encainide therapy, this value was considerably longer (55 1 * 
124 ms, p < O.Ol), and complete VA block was achieved in 
Anterograde conduction. On baseline evaluation, the 
mean shortest paced cycle length with 1:l AV conduction 
was 358 ? 57 ms. On encainide therapy, the shortest atria1 
paced cycle length with 1: 1 AV conduction was significantly 
longer, averaging 409 ? 59 ms (p < 0.01). With isoproterenol 
infusion, anterograde AV node conduction was significantly 
enhanced; the shortest atria1 paced cycle length with 1: 1 AV 
conduction decreased to 313 + 31 ms, which was signifi- 
cantly shorter than that on encainide therapy (p < 0.01) as 
well as at baseline (p = 0.01) (Table 1, Fig. 1B). 
Tacbycardia cycle length. The mean tachycardia cycle 
length during baseline study was 380 ‘_ 49 ms. In the two 
patients in whom sustained tachycardia was inducible on 
encainide therapy, it was slower than at baseline (530 and 
480 versus 300 and 420 ms, respectively). With isoproterenol 
infusion, the tachycardia accelerated in both patients (cycle 
length 380 and 410 ms, respectively). In addition, AV node 
tachycardia became inducible in another eight patients, 
having a mean cycle length of 357 + 42 ms, a value not 
significantly different from the value in the control state 
(402 ? 40, p = NS), (Table 1). 
Sinus cycle length. The mean sinus cycle length was 
761 + 155 ms for all patients during the control study; with 
encainide, it was essentially unchanged at 787 2 102 ms. 
However, during isoproterenol infusion, the mean sinus 
cycle length shortened significantly to 577 2 93 ms (p < 0.01) 
(Table 1). 
Ectopic beats on Holter monitoring. There was a substan- 
tial decrease in the frequency of premature atria1 and ven- 
tricular ectopic beats with encainide (Table 2). The overall 
frequency of premature atria1 beats decreased from 34.1 ? 
90 to 0.16 t 0.27/h, and the average number of premature 
ventricular beats decreased from 25.4 t 51 to 6.6 ? 15/h. 
This decrease was statistically significant for premature 
atria1 beats (p < 0.01) and almost significant for the prema- 
ture ventricular beats (p = 0.04). There was no difference in 
the degree of suppression of ectopic beats between patients 
who had clinical recurrences (Patients 1 to 4,7 to 10 and 14) 
and those who did not (Patients 5, 6, 11 to 13, 15 and 16). 
Follow-up. All patients were followed up for a mean of 
19 2 10 months, (range 2 to 34). Recurrence of AV node 
tachycardia was diagnosed only if documented by electro- 
cardiography (transtelephone or Holter monitoring). Clinical 
episodes were considered inconsequential if they were brief 
(<5 min), self-terminating and accompanied by minimal 
symptoms. If episodes lasted >5 min, required drugs or 
maneuvers for termination or were accompanied by distress- 
ing symptoms, they were considered significant. 
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Table 1. Results of’ Programmed Electrical Stimulation in 16 Patients 
Sinus CL Shortest I: I 
Patient No. (ms) AVC (ms) 
Shortest I: I AVNRT AVNRT 
VAC (ms) Inducible CL (ms) Site of Block 
4 
6 
I2 
13 
I4 
IS 
I6 
Control 
Encainide 
Enc and Iso 
Control 
Encainide 
Enc and Iso 
Control 
Encainide 
Enc and Iso 
Control 
Encainide 
Enc and Iso 
Control 
Encainide 
Enc and Iso 
Control 
Encainide 
Enc and Iso 
Control 
Encainide 
Enc and Iso 
Control 
Encainide 
Enc and Iso 
Control 
Encainide 
Enc and Iso 
Control 
Encainide 
Enc and Iso 
C‘ontrol 
Encainide 
Enc and Iso 
(‘ontrol 
Encainide 
Iinc and Iso 
Control 
Encainide 
Enc and Iso 
Control 
f:nc 
Enc and Iso 
(‘ontrol 
E‘ncainide 
tnc and Iso 
Control 
bncainide 
Enc and Iso 
950 380 
1040 420 
857 - 
790 440 
770 520 
53s 400 
680 450 
860 4x0 
540 - 
750 390 
857 400 
585 320 
600 300 
700 370 
510 - 
710 320 
750 340 
500 260 
800 440 
840 480 
600 <300 
690 320 
890 490 
580 350 
800 410 
740 420 
590 300 
970 400 
960 330 
590 300 
630 <?70 
690 340 
530 .300 
660 350 
810 360 
650 310 
690 340 
670 470 
520 3 IO 
I.200 330 
700 370 
440 300 
620 320 
640 390 
480 320 
620 270 
840 370 
630 300 
3x0 
570 
320 
300 
480 
c300 
350 
760 
10 
<300 
500 
c300 
300 
470 
330 
340 
420 
280 
360 
700 
350 
270 
550 
270 
410 
:>740 
500 
300 
420 
340 
cc 300 
440 
380 
Yes 
NO 
Yes 
Yes 
No 
Yes 
Yes 
No 
No 
Yes 
No 
Yes 
Yes 
No 
No 
Yes 
No 
Yes 
Yes 
No 
Yes 
Yes 
No 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
Yes 
No 
No 
280 Yes 
540 No 
350 Yes 
310 
570 
380 
470 
>700 
330 
290 
410 
280 
410 
540 
510 
Yes 
No 
Yes 
Yes 
No 
Yes 
Yes 
No 
No 
Yes 290 
No - 
No - 
400 
330 
420 
370 
440 
- 
- 
410 
360 
350 
320 
7x0 
3x0 
340 
300 
530 
380 
360 
420 
480 
410 
300 
450 
400 
450 
400 
380 
- 
300 
340 
- 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
and 
anterograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
Retrograde 
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Table 1. (continued) 
Patient No. 
Sinus CL 
(ms) 
Shortest 1: 1 
AVC (ms) 
Shortest 1: 1 
VAC (ms) 
AVNRT 
Inducible 
AVNRT 
CL (ms) Site of Block 
Mean values Control 761 ? 155 358 + 51 337 2 56 380 i- 49 
Encainide 787 + 102 409 2 59* 551 2 124* - 455$ 
Enc and Iso 577 ? 93*+ 313 ? 31*+ 354 + 72t - 353 + 42 
*p < 0.01 versus control; tp i 0.01 versus encainide; $two patients only. AVNRT = atrioventricular node sustained reentrant tachycardia; CL = cycle length; 
Enc = encainide: Iso = isoproterenol: shortest 1:l AVC = shortest atrial pacing cycle length with 1:l anterograde conduction; Shortest 1:l VAC = shortest 
ventricular pacing cycle length with 1: I retrograde conduction: Site of block = site of block on encainide therapy during nonsustained tachycardia or during 
introduction of premature atrial extrastimuli. 
Figure 1. A, Effect of encainide on retrograde atrioventricular (AV) 
node conduction (VA) and reversal of the encainide effect by 
isoproterenol. B, Effect of encainide on anterograde AV node 
conduction and reversal of the encainide effect by isoproterenol. CL 
= cycle length. 
775 
- I 
725 
0 
-I 3 600 ’ 
UE 
“4 a 550 . 
SF 
E ii 500 . 
+n 
=z 
go ” 450 ’ 
250 v 
Control Encainide Encainide & 
lsoproterenol 
600 
Control Encainide Encainide & 
lsoproterenol 
Tachycardia recurrence. Seven patients had no clinical 
episodes during a mean follow-up period of 14 2 10 months. 
None of these patients had AV node tachycardia inducible 
with programmed stimulation while receiving encainide, and 
in five of these patients, tachycardia had not been inducible 
even during isoproterenol infusion. 
Five patients had fleeting inconsequential episodes dur- 
ing a mean follow-up period of 23 ? 9 months. The AV node 
tachycardia had not been inducible with programmed stim- 
ulation during encainide therapy in any of these patients, but 
after isoproterenol infusion, it could be initiated in four 
patients. No change in treatment was required in any of 
these patients because recurrences were infrequent and 
associated with minimal, if any, symptoms. 
The four remaining patients had signijicant tachycardia 
episodes while taking encainide during a mean follow-up 
period of 26 + 5 months. Tachycardia had not been inducible 
during encainide therapy in two of these patients. Slow AV 
node tachycardia (cycle length 530 and 480 ms, respectively) 
had been initiated with programmed stimulation in the re- 
maining two patients. With isoproterenol infusion, tachycar- 
dia was initiated in both patients with previously noninduc- 
ible arrhythmia and accelerated significantly (to a cycle 
length of 380 and 410 ms, respectively) in the remaining two 
patients. All four patients continued to have clinical episodes 
with unabated frequency, although symptoms were dimin- 
ished during these episodes. Clinical control was achieved 
by implantation of an atria1 antitachycardia pacemaker in 
one patient, and by transcatheter ablation of the His bundle 
in another. The severity of clinical episodes was decreased 
Table 2. Suppression of Ectopic Activity With Encainide During 
Halter Monitoring 
Control Encainide 
PACih 34.1 % 90 0.16 t 0.27* 
PVC/h 25.4 + 51 6.6 ? 15t 
AVNRT/day 57 ? 225 0.06 ? 0.25* 
*p < 0.01 versus control: tp = 0.04 versus control. All values given as 
mean values + 1 SD. AVNRTiday = episodes of atrioventricular node 
reentrant tachycardiaiday; PACih = premature atrial complexes/h; PVC/h = 
premature ventricular complexes/h. 
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in the remaining two patients with encainide therapy, but 
clinically significant episodes persisted. Nadolol (40 mgiday) 
was added to their regimen; no further recurrences were 
subsequently noted. 
Side effects. Side effects were limited to dizziness (six 
patients) and headaches (three patients). Symptoms resolved 
spontaneously within a few days in five patients, and re- 
sponded to a reduction in dosage in the remaining three 
patients. 
Discussion 
Several antiarrhythmic agents have been used to treat AV 
node reentrant tachycardia. Although usually well tolerated, 
digoxin and calcium channel blockers have not proved 
effective over the long-term in a sizable percentage of 
patients (8-11). Type la agents (for example, procainamide, 
quinidine and disopyramide) have proved to be more effec- 
tive (8,12,13), but patient acceptance has been limited by 
frequent side effects. Encainide is known to have few side 
effects (14,15), yet appeared to be highly effective in this 
trial. The AV node tachycardia not responsive to multiple 
other antiarrhythmic agents was successfully controlled in 
75% of patients. In another 12.5% of patients, control was 
achieved with the addition of a beta-blocker to the regimen 
(beta-blockers alone had proved to be ineffective in these 
patients). Side effects were minimal at these therapeutic 
dosages. 
Re\jrrsal of’ the encainide antiarrh~~thmic eflect with 
isoproterenol infusion may also have important clinical 
implications. Endogenous catecholamine surges (for exam- 
ple, in response to exercise) are likely to produce effects 
similar to those of isoproterenol. Thus, the antiarrhythmic 
efficacy of encainide may not be absolutely uniform; fluctu- 
ations in endogenous catecholamine levels or sympathetic 
tone may partially or completely reverse the drug effect. 
Autonomic modulation of the encainide effect may explain 
why inducibility of AV node tachycardia during isoprotere- 
nol infusion (when the arrhythmia was not inducible with 
encainide alone) seemed to predict future clinical recur- 
rences. whereas lack of inducibility with isoproterenol ap- 
peared to be predictive of good clinical control. 
Mode of action. The induction and sustainment of reentry 
within the AV node depend on a balance between conduc- 
tion and refractoriness in the various limbs of the reentrant 
circuit (16). Encainide appeared to prevent AV node tachy- 
cardia by negating this balance, primarily by prolonging 
conduction and permitting block in the retrograde fast limb 
of the circuit. In this respect. it resembled type la agents but 
differed from digitalis, calcium channel blockers and beta- 
blockers, which usually have more pronounced effects on 
the anterograde pathway (8-13,17,18). 
As a corollary, it seems probable that a beta-adrenergic 
blocker may prove to be an important adjunct in achieving 
more reliable and stable antiarrhythmic efficacy, as occurred 
in two cases in this series. It is likely that the effect of other 
antiarrhythmic agents on the AV node can be similarly 
reversed with isoproterenol because the mechanisms and 
sites of action at the cellular level are similar in many cases. 
Indeed. such reversal has already been demonstrated in the 
case of procainamide in this laboratory (22). and similar data 
have been published regarding amiodarone (2). 
Encuinide also considerably decreased the ,frequency sf 
premature atria1 and ventricular beats in most patients 
(Table 2). This may have contributed to its effectiveness in 
reducing the number of clinical episodes. However. this 
effect by itself is unlikely to completely prevent significant 
clinical episodes because ectopic atria1 and ventricular beats 
(which may “trigger” the arrhythmia) were not completely 
eliminated in most patients. Furthermore, the frequency of 
ectopic beats after encainide was no different in patients with 
and without significant clinical recurrences. 
Role of exercise stress testing. During exercise testing 
while receiving encainide. none of the patients had recur- 
rence of the arrhythmia, although isoproterenol was able to 
reverse encainide effect in all but two patients, and sympa- 
thetic stimulation during exercise would be expected to have 
a similar effect. These findings can be explained by the 
relatively brief duration of exercise and the absence of 
critically timed ectopic beats occurring during this time to 
initiate tachycardia, as a result of the suppressant effect of 
encainide. Only three patients had AV node tachycardia 
during exercise while taking no drugs. indicating that even in 
the absence of drugs, critically timed ectopic beats capable 
of triggering a tachycardia episode occurred relatively 
rarely. 
Reversal of drug effects with isoproterenol. In the doses Conclusions. It is concluded that 1) Encainide is highly 
utilized, isoproterenol appeared to reverse the antiarrhyth- effective in the treatment of resistant paroxysmal AV node 
mic effect of encainide on anterograde and retrograde con- reentrant tachycardia. even when other drugs have failed. 2) 
duction as well as tachycardia inducibihty. Although isopro- The efficacy of encainide is chietly due to its depressant 
terenol is known to enhance AV node conduction in the effect on retrograde AV node conduction. with production of 
unmedicated state (19). reversal of the encainide effect on block in the retrograde pathway in AV node reentrant 
the AV node by isoproterenol has not been previously 
demonstrated. The exact mechanism by which this reversal 
was accomplished remains unclear. Facilitation of calcium- 
dependent currents due to beta-adrenoceptor stimulation by 
isoproterenol may constitute a possible mechanism (20,21). 
Clinical implications. Our results suggest that encainide 
is an effective agent for control of AV node reentrant 
tachycardia. even when the arrhythmia is refractory to other 
agents. In view of its superior side effect profile, encainide 
should be considered a first line agent for this arrhythmia. 
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tachycardia. 3) Encainide-induced depression of AV node 
conduction is reversed by isoproterenol; increased sympa- 
thetic tone is likely to have the same effect. 4) A beta- 
adrenergic blocker may serve as a valuable adjunct to 
encainide therapy. 5) The lack of inducibility of the arrhyth- 
mia during isoproterenol infusion (in the presence of encai- 
nide) is predictive of long-term clinical control of tachycar- 
dia. 6) The initiation of tachycardia with isoproterenol 
infusion (despite encainide usage) indicates increased likeli- 
hood of clinical recurrences. 
I. 
2. 
3. 
4. 
5. 
6. 
I. 
8. 
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